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BACKGROUND: Oncogenic BRAF mutation had been considered to be a founder event in the formation of melanocytic tumours;
however, we recently argued against this notion by showing marked polyclonality of BRAF mutations in acquired melanocytic nevi
(Lin et al, J Natl Cancer Inst., 2009; 101:1423–7). Here, we tested whether similar heterogeneity of BRAF mutations exists in primary
melanomas.
METHODS: We isolated and sequenced single melanoma cells from five primary melanoma tissues using antibodies against human
high-molecular-weight melanoma-associated antigen. We also examined 10 primary melanomas by the sensitive Mutector assay
detecting the BRAF
V600E mutation, as well as by cloning and sequencing of separated alleles. Furthermore, we estimated the
frequency of BRAF mutant alleles in paired samples of primary tumour and recurrence or metastasis in three patients.
RESULTS: Single-cell mutation analyses revealed that four of five primary melanomas contained both BRAF-wild-type and BRAF-mutant
tumour cells. Tumour heterogeneity in terms of BRAF mutations was also shown in 8 of 10 primary melanomas. Selection of BRAF
mutant alleles during progression was demonstrated in all the three patients.
CONCLUSION: Acquisition of a BRAF mutation is not a founder event, but may be one of the multiple clonal events in melanoma
development, which is selected for during the progression.
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Among the several genetic alterations governing melanoma
initiation and progression so far identified, the serine/threonine-
specific protein kinase BRAF is thought to be a key player because
it is activated by somatic mutations in 50–70% of cutaneous
melanomas. A substitution of glutamic acid for valine at codon 600
(V600E) is the most common BRAF mutation in melanoma,
occurring in over 90% of BRAF-mutated cases (Davies et al, 2002).
BRAF
V600E constitutively activates the RAS/RAF/MEK/ERK signal-
ling pathway, and stimulates transformation of immortalised
melanocytes (Wellbrock et al, 2004). Interestingly, the BRAF
V600E
mutation was also found in over 80% of melanocytic nevi,
suggesting that mutational activation of the RAS/RAF/MEK/ERK
pathway is a critical step in the initiation of melanocytic neoplasia
(Pollock et al, 2003). Moreover, a mouse model of melanocytic
nevus and melanoma, which is driven by the inducible expression
of BRAF
V600E in melanocytes, has been developed recently,
providing further evidence that the acquisition of a BRAF
mutation can be a founder event in melanocyte transformation
(Dhomen et al, 2009). Based on these observations, a number of
Raf kinase inhibitors, as well as a selective inhibitor of active B-Raf
kinase have been developed and tested in clinical settings
(reviewed in Gray-Schopfer et al, 2007; Wellbrock and Hurlstone,
2010).
Very recently, however, we have demonstrated marked poly-
clonality of BRAF mutations in acquired melanocytic nevi, which
argues against the possibility that a mutation in BRAF is an initial
event in melanocyte transformation (Lin et al, 2009). In this study,
we have tested whether a similar heterogeneity of BRAF mutations
exists in primary melanomas.
MATERIALS AND METHODS
Tissues
The study was approved by the medical ethics committee of the
Shinshu University School of Medicine, and conducted according
to the Declaration of Helsinki Principles. Primary and metastatic
melanoma tissues were obtained from 17 patients. Case 17 was an
autopsy case. For excisions, all patients gave written informed
consent.
Cell line
A melanoma cell line (MMG1) established from a primary acral
melanoma was kindly provided by Professor Akifumi Yamamoto
(Saitama Medical Collage Cancer Center, Saitama, Japan). The cells
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swere maintained in RPMI 1640 medium containing 10% fetal
bovine serum. Tyrosinase expression was confirmed by RT–PCR.
This cell line was tumourigenic in NOD/SCID mice. Passages of
4150 were used throughout this experiment. Although melanoma
cell lines frequently show copy number increase at chromosome 7q
where the BRAF gene resides (Tanami et al, 2004), array CGH
analysis of MMG1 revealed no copy number aberrations at 7q
(data not shown).
Immunomagnetic cell isolation
Fresh tissues of five primary melanomas (PM-1–5) were used for
isolation of pure melanoma cells by using an antibody cocktail of
human high-molecular-weight melanoma-associated antigen
(HMW-MAA) (a gift from Dr Soldano Ferrone, University of
Pittsburgh Cancer Institute) and immunomagnetic beads, as
described previously (Lin et al, 2009).
Microdissection and DNA extraction
Primary melanoma cells separated by immunomagnetic beads
and MMG1 cells were smeared on a film-coated glass slide
(Maiwafosis Co. Ltd, Osaka, Japan), stained with methylene blue
and subjected to laser-capture microdissection using a PALM-MB
microdissection system (PALM Microlaser Technologies,
Bernried, Germany). For the frozen tissues of primary and
metastatic melanoma, 6-mm-thick cryosections stained with
methylene blue were manually microdissected on an inverted
microscope to select the areas in which at least over 75% of cells
were tumour cells. For formalin-fixed paraffin-embedded tissues,
we carried out laser-capture microdissection to collect pure
tumour cell populations with the aid of gp100 immunostaining
using an antibody to gp100 (Zymed, San Francisco, CA, USA) and
the DAKO Envision System (DAKO Japan Co. Ltd, Kyoto, Japan).
DNA was extracted as described previously (Ichii-Nakato et al,
2006; Lin et al, 2009).
PCR for BRAF exon 15
Procured single-melanoma cell samples were amplified for exon 15
of the BRAF gene with a hemi-nested PCR (Lin et al, 2009). DNA
extracted from frozen or paraffin-embedded tissues was amplified
by a conventional PCR (Ichii-Nakato et al, 2006). The PCR
amplicons were purified using the QIAquick PCR purification kit
(Qiagen Inc., Tokyo, Japan).
Subcloning
The TA cloning was done with the TOPO XL PCR Cloning Kit
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. After incubation at 371C overnight, colonies were
picked up randomly from the plate, confirmed for correct
recombination by PCR and inoculated into 3ml of LB medium
containing 50mgml
 1 kanamycin. After incubation at 371C
overnight with vigorous shaking, the bacterial cells were harvested
and purified using the QIAprep Spin Miniprep kit (Qiagen Inc.).
Sequence analysis and identification of mutations
The purified PCR amplicons and recombinant plasmid DNA were
sequenced using the BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA) and analysed on an
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
Mutector assay
DNA samples from primary melanomas were analysed for the
BRAF
V600E mutation by a sensitive shifted termination assay using
the Mutector kit (TrimGen Corporation, Sparks, MD, USA)
following the manufacturer’s instructions (Ichii-Nakato et al,
2006).
RESULTS
To investigate whether primary melanoma cells are homogenous
or heterogeneous in terms of BRAF mutation, we first carried out
immunomagnetic isolation of single melanoma cells from five
fresh primary melanoma tissues using melanoma-specific human
HMW-MAA monoclonal antibodies followed by PCR and sequen-
cing, as previously described (Lin et al, 2009). High–molecular-
weight melanoma-associated antigen is known to be expressed in
490% of melanomas, although the frequency is somewhat lower
in acral melanomas (Campoli et al, 2004). Although HMW-MAA is
also expressed in skin cells within hair follicles and epidermal
basal cell layer, endothelial cells and pericytes (Campoli et al,
2004), we obtained virtually no cells from normal skin samples in
our previous control experiments using the same cocktail of
HMW-MAA-specific monoclonal antibodies (Lin et al, 2009).
Single melanoma cells were selectively captured by immuno-
magnetic beads and procured by laser-capture microdissection
(Supplementary Figure S1a). The tumours examined included
three acral melanomas and two melanomas on non-chronically
sun-damaged skin (Table 1). In four of the five primary
melanomas, although the majority of the cells were BRAF-wild
type, we observed a substantial number of melanoma cells
harbouring the V600E mutation. Furthermore, two primary
melanomas (cases 1 and 3) also contained tumour cells with other
BRAF mutations, such as K601R, V600M and V600-K601E, all of
which have been reported in melanoma (Garnett and Marais, 2004)
(Supplementary Figure S1b). The V600-K601E mutations was
shown to induce high BRAF kinase activity (Hou et al, 2007),
whereas the activity of the K601R and V600M mutations have not
been tested (Garnett and Marais, 2004). In one acral melanoma
(case 5) all the separated melanoma cells were wild type. A primary
melanoma cell line MMG1 also showed BRAF mutation hetero-
geneity (Table 1). Detection of the homozygous BRAF
V600E
mutation in a few single cells was considered to be partly
due to the failure of PCR to amplify the wild-type allele, that is,
allele drop-out (ADO), which is a common problem in single-cell
PCR (Piyamongkol et al, 2003). Although some of the wild-type
sequences detected in this experiment may also be explained
by the ADO of mutant alleles, it is obvious that the large number of
wild-type sequences detected in melanoma tissues cannot
be explained by ADO alone. As for MMG1, the ratio of 10:1 for
wild-type BRAF and homozygous V600E mutation was signifi-
cantly uneven by the two-tailed binominal test (P¼0.012),
indicating that the result is unlikely to be due to ADO (the null
hypothesis here was that all the cells containing wild-type BRAF
and homozygous BRAF mutation were artifacts by ADO, on the
premise that the chance of ADO was the same for a mutant allele
and a wild-type allele). Contamination of non-melanoma cells by
non-specific binding to immunobeads was unlikely, because we
had previously tested and confirmed the specificity of immuno-
magnetic cell isolation using anti-HMW-MAA antibodies (Lin
et al, 2009). Thus, the results indicate that most primary
melanomas are polyclonal, consisting of BRAF-mutant, as well as
BRAF-wild-type tumour cells. BRAF mutation heterogeneity
observed in the primary melanoma cell line MMG1 strongly
supports this conclusion.
To further reveal the heterogeneity of BRAF mutations within
primary melanoma, we examined 10 tumours (one melanoma on
chronic sun-damaged skin, four melanomas on non-chronic sun-
damaged skin, two acral melanomas and three mucosal melano-
mas) by the sensitive Mutector assay detecting the BRAF
V600E
mutation (TrimGen Corporation), as well as by cloning and
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ssequencing of separated alleles (Table 2). We obtained relatively
pure tumour cell populations by manual microdissection or laser-
capture microdissection with the aid of gp100 immunostaining
(Supplementary Figure S1c). Conventional direct sequencing of
PCR products of BRAF exon 15 revealed that three tumours
harboured the V600E mutation, one tumour had the V600K
mutation, and the remaining six tumours were wild type. However,
the sensitivity of detecting heterozygous mutations in conventional
direct sequencing is rather low, as tested in our previous study
(Ichii-Nakato et al, 2006); the mutant peak is reliably discernable
only when heterozygous mutant cells comprised 420% of
samples. As expected, the more sensitive Mutector assay, which
can detect as little as 5% of heterozygous BRAF
V600E mutation
(Ichii-Nakato et al, 2006), showed positive results in five tumours
that were wild type by direct sequencing. The result suggests that a
substantial number of primary tumours, labelled as BRAF-wild
type by conventional direct sequencing, actually contain a small
fraction of BRAF
V600E cells. The tumour in case 6, which mostly
consisted of cells with the BRAF
V600K mutation, may also contain a
small fraction of BRAF
V600E cells, as the Mutector assay was
positive. To directly demonstrate such a small fraction of mutant
alleles, we cloned the PCR amplicons of BRAF exon 15 and
sequenced individual alleles. A total of 40 bacterial subclones were
sequenced for each sample. As expected, all the samples that
showed wild type by direct sequencing but positive for the
Mutector assay contained 2–7 BRAF
V600E mutant alleles (Supple-
mentary Figure S1d). One BRAF
V600E mutant allele was detected
in the tumour in case 6, while the V600K mutation prevailed in this
tumour. Two primary melanomas (cases 12 and 13) had minor
BRAF mutant alleles other than V600E, such as K601E and V600K.
These results further confirmed the heterogeneity of BRAF
mutations within primary melanomas.
To examine whether BRAF mutant alleles are selected for in
melanoma progression, we enumerated BRAF mutant alleles by
subcloning in three cases where the pairs of primary tumour and
recurrent primary tumour or metastases were available for
analyses (Table 3). RPM-10 was a recurrence of a primary tumour
PM-10 that developed 3 years later. Sequencing of bacterial
colonies showed an increase of BRAF
V600E mutant alleles in the
recurrent tumour; this was reflected in the change in the results of
direct sequencing from wild type to the BRAF
V600E mutation.
In case 16, V600-K601E alleles found in the primary tumour
increased in the lymph node metastasis. Case 17 was an autopsy
case. The primary tumour of this case (PM-17) was wild type for
BRAF by conventional sequencing. However, sequencing of as
many as 80 cloned PCR amplicons revealed a small fraction of
V600K mutant alleles, which were predominated in seven out of
nine metastases, each obtained from different anatomical sites.
These results strongly suggest the selection of BRAF mutant alleles
in melanoma progression, as reported by others (Dong et al, 2003;
Kirschner et al, 2005).
DISCUSSION
Since the discovery of frequent activating BRAF mutations in
melanoma (Davies et al, 2002), myriads of papers have published
reporting the detection of BRAF mutations in melanoma (reviewed
Table 1 Polyclonality of BRAF mutations in primary melanoma as revealed by single-cell PCR and sequencing
Sample no. Age (years) Sex
Type of
melanoma
No. of cells with
heterozygous
BRAF mutations
a
No. of cells with
homozygous
BRAF mutations
a
No. of cells with
wild-type BRAF
Total no. of
cells
PM-1 — F Acral 7 (V600E)+2 (K601R) 2 (V600E) 45 56
PM-2 21 F NCSD 14 (V600E) 3 (V600E) 31 48
PM-3 53 F NCSD 4 (V600E)+3 (V600M) 3 (V600E)+2(V600-K601E) 40 52
PM-4 85 F Acral 8 (V600E) 1 (V600E) 41 50
PM-5 47 F Acral 0 0 50 50
MMG1 — — Acral 29 (V600E) 1 (V600E) 10 40
Abbreviations: Acral¼acral melanoma; MMG1¼a cell line established from primary acral melanoma; NCSD¼melanoma on non-chronic sun-damaged skin; PM¼primary
melanoma.
aV600E, T1799A; K601R, A1802G; V600M, G1798A; V600-K601E ,TGA1799-1801del.
Table 2 Polyclonality of BRAF mutations in primary melanoma as revealed by the Mutector assay and subcloning
Subcloning
c
Sample no.
Age
(years) Sex
Tumour
thickness (mm)
Type of
melanoma Tissue
a
Direct
sequencing
Mutector
(OD ratio)
b
No. of colonies
with mutant BRAF
No. of colonies
with wild-type BRAF
PM-6 85 M 13 CSD FFPE V600K Positive (8.9) 18 (V600K)+1 (V600E) 21
PM-7 57 M 4.8 NCSD FFPE Wild type Positive (9.04) 3 (V600E) 37
PM-8 68 F 4.1 NCSD FFPE Wild type Negative (0.53) 0 40
PM-9 29 F 4 NCSD Frozen V600E Positive (32.51) 20 (V600E) 20
PM-10 32 F 0.8 NCSD FFPE Wild type Positive (4.75) 2 (V600E) 38
PM-11 50 M 4.1 Acral FFPE Wild type Positive (14.47) 7 (V600E) 33
PM-12 69 F 3.5 Acral FFPE V600E Positive (27.34) 18 (V600E)+1 (V600K) 21
PM-13 77 F 1.5 Mucosal Frozen V600E Positive (31.69) 9 (V600E)+1 (K601E) 30
PM-14 74 F 30 Mucosal Frozen Wild type Positive (8.64) 2 (V600E) 38
PM-15 79 F 6 Mucosal FFPE Wild type Negative (0.17) 0 40
Abbreviations: Acral¼acral melanoma; CSD¼melanoma on chronic sun-damaged skin; FFPE¼formalin-fixed paraffin-embedded tissues; MMG1¼a cell line established from
primary acral melanoma; Mucosal¼mucosal melanoma; NCSD¼melanoma on non-chronic sun-damaged skin; PM¼primary melanoma.
aAll the FFPE sections were stained
with gp100 protein, and pure tumour tissues were collected by laser microdissection.
bOD ratio 42 were regarded as positive (Ichii-Nakato et al, 2006).
cA total of 40 bacterial
colonies were sequenced for each sample. V600E, T1799A; V600K, GT1798-99AA; K601E, A1801G.
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sin Hocker and Tsao, 2007). These include the landmark paper that
described marked difference of BRAF mutation frequencies in the
different types of melanoma; that is, B60% of melanomas on non-
chronic sun-damaged skin had BRAF mutations, whereas the
mutations were rather infrequent (11–23%) in melanomas on
chronic sun-damaged skin, mucosa and acral skin (Curtin et al,
2005). However, most of these previous studies utilised PCR and
direct sequencing in the mutation detection, which could not
reliably detect heterozygous BRAF mutations when the DNA
samples contained o20% of mutant cells (Ichii-Nakato et al, 2006;
Houben et al, 2008). Thus, it is possible that many melanomas
labelled as wild-type BRAF by direct sequencing may carry
mutations, albeit at low levels below the sensitivity of the method
(Greene et al, 2009). In this study, we employed three different
methods, including single-cell mutation analysis, shifted termina-
tion assay (Mutector) and subcloning, all of which were sensitive
enough to detect minor mutant alleles. We actually demonstrated a
small population of melanoma cells harbouring activating BRAF
mutations in a substantial number of tumours that were wild type
by direct sequencing. Most of the mutations found were V600E,
but several other mutations were also identified, such as V600K,
V600M, V600-K601E and K601E, all of which had been reported
previously in melanomas (Garnett and Marais, 2004). Thus, most
primary melanoma lesions so far examined consist of melanoma
cells that contained wild-type BRAF admixed with melanoma cells
that contained V600E and other BRAF mutations.
In vivo and in vitro experiments have shown that activating
BRAF mutations, such as V600E, stimulate constitutive cell
signalling, growth factor-independent proliferation and transfor-
mation of immortalised melanocytes (Hingorani et al, 2003;
Wellbrock et al, 2004; Hoeflich et al, 2006). Thus, it may be
surprising that melanoma cells acquiring activating BRAF muta-
tions constitute only a minor subpopulation of primary tumours
and do not outgrow BRAF-wild-type cells. One possible explana-
tion is that these cells with BRAF mutations undergo senescence,
as has been demonstrated in melanocytic nevus (Michaloglou et al,
2005; Gray-Schopfer et al, 2006). However, this is unlikely because
the minor population of melanoma cells with BRAF mutations
became predominant in a recurrent primary tumour or metastases
that developed in the same patients (Table 3). Furthermore, the
expression of IGFBP7, which induces senescence in melanocytes
acquiring the BRAF
V600E mutation, was not observed in
BRAF
V600E-positive melanoma tissues, whereas BRAF
V600E-positive
nevi expressed high levels of IGFBP7 (Wajapeyee et al, 2008).
Another possibility is that RAS/RAF/MEK/ERK signalling is still
subject to regulation in melanoma cells even in the presence of
constitutively active BRAF. It has recently been shown that the
phospho-ERK staining was not correlated with the mutational
status of NRAS and/or BRAF in melanoma tissues, and that
cultured BRAF-mutant melanoma cells downregulated RAS/RAF/
MEK/ERK activation when cultured at high densities or under
non-adherent conditions (Houben et al, 2008).
The finding of the selection of mutant BRAF alleles in melanoma
progression appears to be significant in view of the recent
development of selective BRAF
V600E kinase inhibitors (Sala et al,
2008; Tsai et al, 2008) that showed successful preliminary clinical
results (Flaherty et al, 2010). Although BRAF mutations are
thought to be rare in acral and mucosal melanomas (Curtin et al,
2005), primary tumours of these types of melanomas frequently
contain minor populations of BRAF-mutant clones, which are
likely to predominate in metastases. It is therefore crucial to
genotype metastatic tumours before administrating BRAF
V600E-
selective drugs to identify patients who are likely to respond.
Finally, polyclonality of BRAF mutations in primary melanomas
indicates that BRAF mutation is not a founder event in
melanomagenesis. As has been recently shown in acute lympho-
cytic leukaemia (Greaves, 2009), it is speculated that precancerous
melanocytes already harbouring an unknown first hit may
subsequently acquire multiple driver mutations; thus, the acquisi-
tion of BRAF mutation might be one of these secondary events.
BRAF-wild-type clones present in primary tumours and metastases
are likely to contain mutations or copy number alterations
affecting genes other than BRAF, such as NRAS, KIT, cyclin D1,
PTEN and CDKN2A (Curtin et al, 2005, 2006). Future studies
examining mutation profiling on a single-cell level (Greaves, 2009)
would reveal a complex clonal evolution in melanoma develop-
ment and progression.
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